Jack is currently CEO of ImmunogenX and has over 25 years of experience in creating and leading the development of innovative technologies particularly in the field of analytical instrumentation. Previously he founded Syagen Technology, Inc. and led its growth culminating in the successful acquisition in 2011 by the $18B/yr French company Safran. Jack sits on the Board of Directors of Flamentera AG, Advanced Telesensors, and Appellation Ventures. Jack has published over 120 papers, delivered over 80 invited talks, has about 30 U.S. patents issued or pending.
ImmunogenX is a clinical-stage therapeutic and diagnostic company focused on celiac disease (CD). These represent unmet needs for a critical disease that is incurable, afflicts about 1% of the world’s population, and incurs huge health costs. Our therapeutic solution latiglutenase is based on a proven mixture of digestive enzymes that degrades gluten proteins in the body. It has gone through several successful clinical trials and is posed to be first to market with revenue potential >$1B/year. Our diagnostic CypCel is the only minimally-invasive method to monitor the state of health of the intestine in treated CD patients with the potential to address other gastrointestinal ailments.